Boston Scientific Co. (NYSE:BSX) Shares Purchased by Thematics Asset Management

Thematics Asset Management boosted its holdings in Boston Scientific Co. (NYSE:BSX) by 2.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 107,804 shares of the medical equipment provider’s stock after acquiring an additional 2,328 shares during the period. Thematics Asset Management’s holdings in Boston Scientific were worth $9,629,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BSX. Tradition Wealth Management LLC boosted its position in Boston Scientific by 2.2% during the 4th quarter. Tradition Wealth Management LLC now owns 5,510 shares of the medical equipment provider’s stock valued at $492,000 after purchasing an additional 121 shares during the period. Transce3nd LLC bought a new position in shares of Boston Scientific during the fourth quarter worth about $150,000. MML Investors Services LLC lifted its position in Boston Scientific by 21.2% in the 4th quarter. MML Investors Services LLC now owns 107,648 shares of the medical equipment provider’s stock valued at $9,615,000 after purchasing an additional 18,840 shares during the last quarter. MetLife Investment Management LLC boosted its stake in Boston Scientific by 1.9% during the 4th quarter. MetLife Investment Management LLC now owns 390,012 shares of the medical equipment provider’s stock valued at $34,836,000 after purchasing an additional 7,152 shares during the period. Finally, NWK Group Inc. increased its stake in shares of Boston Scientific by 2.1% in the fourth quarter. NWK Group Inc. now owns 75,724 shares of the medical equipment provider’s stock valued at $6,764,000 after purchasing an additional 1,571 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $105.48, for a total transaction of $1,265,760.00. Following the transaction, the director now directly owns 24,398 shares in the company, valued at $2,573,501.04. This trade represents a 32.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Daniel J. Brennan sold 15,087 shares of the company’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $105.07, for a total value of $1,585,191.09. Following the sale, the chief financial officer now owns 241,451 shares of the company’s stock, valued at approximately $25,369,256.57. This trade represents a 5.88 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 133,183 shares of company stock valued at $13,948,476. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Down 0.2 %

Boston Scientific stock opened at $95.08 on Friday. The firm’s 50 day moving average price is $99.46 and its two-hundred day moving average price is $94.41. The firm has a market cap of $140.63 billion, a PE ratio of 76.06, a P/E/G ratio of 2.79 and a beta of 0.73. Boston Scientific Co. has a twelve month low of $66.80 and a twelve month high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Piper Sandler raised their target price on Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Truist Financial cut their price objective on shares of Boston Scientific from $120.00 to $113.00 and set a “buy” rating on the stock in a research note on Friday, April 11th. Needham & Company LLC raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $113.00 target price on the stock in a research note on Wednesday. UBS Group increased their price objective on shares of Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a report on Friday, February 7th. Finally, Barclays upped their target price on Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $110.22.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.